309 related articles for article (PubMed ID: 7579739)
1. Proximal renal tubular acidosis secondary to FK506 in pediatric liver transplant patients.
O'Gorman MA; Fivush B; Wise B; Colombani P; Burdick J; Schwarz KB
Clin Transplant; 1995 Aug; 9(4):312-6. PubMed ID: 7579739
[TBL] [Abstract][Full Text] [Related]
2. Distal tubular acidosis induced by FK506.
Heering P; Ivens K; Aker S; Grabensee B
Clin Transplant; 1998 Oct; 12(5):465-71. PubMed ID: 9787958
[TBL] [Abstract][Full Text] [Related]
3. Toxicity versus rejection--or why conversions between cyclosporine A and FK506 were performed after liver transplantation.
Platz KP; Mueller AR; Jonas S; Blumhardt G; Bechstein WO; Lobeck H; Neuhaus HL
Clin Transplant; 1995 Jun; 9(3 Pt 1):146-54. PubMed ID: 7549052
[TBL] [Abstract][Full Text] [Related]
4. Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects.
Asante-Korang A; Boyle GJ; Webber SA; Miller SA; Fricker FJ
J Heart Lung Transplant; 1996 Apr; 15(4):415-22. PubMed ID: 8732602
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
6. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study.
Rinaldi M; Pellegrini C; Martinelli L; Goggi C; Gavazzi A; Campana C; Arbustini E; Grossi P; Regazzi M; Ippoliti G; Vigano M
J Heart Lung Transplant; 1997 Oct; 16(10):1001-10. PubMed ID: 9361242
[TBL] [Abstract][Full Text] [Related]
7. Renal function in pediatric liver transplant patients.
McDiarmid SV
Kidney Int Suppl; 1996 Jan; 53():S77-84. PubMed ID: 8770996
[TBL] [Abstract][Full Text] [Related]
8. Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report.
Ogita K; Takada N; Taguchi T; Suita S; Soejima Y; Suehiro T; Shimada M; Maehara Y
Asian J Surg; 2003 Oct; 26(4):218-20. PubMed ID: 14530108
[TBL] [Abstract][Full Text] [Related]
9. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
[TBL] [Abstract][Full Text] [Related]
10. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
12. [Slowing progression of chronic allograft nephropathy by conversion from cyclosporin A to tacrolimus].
Peng LK; Xie XB; Peng FH; Wang Y; Jiang Y; Lan GB; Fang CH; Nie MH
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):59-62. PubMed ID: 17344588
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study of tacrolimus in postoperative treatment of patients with renal transplantation for diabetic end-stage renal disease].
Yu LX; Shan HT; Fu SJ; Du CF; Ma JJ; Xu J; Deng WF; Wang YB
Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1146-8. PubMed ID: 14625173
[TBL] [Abstract][Full Text] [Related]
14. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
[TBL] [Abstract][Full Text] [Related]
15. The role of testosterone in cyclosporine-induced osteopenia.
Bowman AR; Sass DA; Dissanayake IR; Ma YF; Liang H; Yuan Z; Jee WS; Epstein S
J Bone Miner Res; 1997 Apr; 12(4):607-15. PubMed ID: 9101372
[TBL] [Abstract][Full Text] [Related]
16. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506.
Platz KP; Mueller AR; Blumhardt G; Bachmann S; Bechstein WO; Kahl A; Neuhaus P
Transplantation; 1994 Jul; 58(2):170-8. PubMed ID: 7518975
[TBL] [Abstract][Full Text] [Related]
17. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506?
Mueller AR; Platz KP; Blumhardt G; Bechstein WO; Steinmüller T; Christe W; Hopf U; Lobeck H; Neuhaus P
Clin Transplant; 1995 Jun; 9(3 Pt 1):176-84. PubMed ID: 7549057
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
19. [Application of tacrolimus and cyclosporine A in HBV-carrying renal transplant recipients].
Liu XY; Yu LX; Fu SJ; Xu J; Du CF; Deng WF; Wang YB; Ye GR; Zhang YX
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):1090-2. PubMed ID: 17666359
[TBL] [Abstract][Full Text] [Related]
20. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
